32 results on '"Charokopou, M."'
Search Results
2. PNS28 ADVANCING VALUE ASSESSMENTS: HOW CAN A PARADIGM OF VALUE MEASUREMENT BEYOND QALY BE ENHANCED TO HOLISTICALLY CAPTURE WHAT TRULY MATTERS TO PATIENTS AND PAYERS?
3. PMS43 - AN ECONOMIC VALUE FRAMEWORK TO ASSESS THE COST EFFECTIVENESS OF FRACTURE PREVENTION TREATMENTS IN PATIENTS WITH OSTEOPOROSIS AT IMMINENT RISK OF FRACTURE
4. PCP14 - VALUE FRAMEWORKS AND PRICING SETTING; CAN THEY CO-EXIST?
5. Lacosamide As First Line Treatment Option In Focal Epilepsy; A Cost-Utility Analysis for The Greek Healthcare System
6. Risk of Major Osteoporotic Fracture (Hip, Vertebral, Radius, Humerus [MOF]) After First, Second and Third Fragility Fracture In A Swedish General Population Cohort
7. Cost-Effectiveness of Brivaracetam As Adjunctive Therapy for Partial-Onset Epilepsy In The Finnish Setting
8. Relative Efficacy and Tolerability of Lacosamide Versus Levetiracetam as Monotherapy for Adults with Newly Diagnosed Focal Seizures: A Post-Hoc Analysis of Randomized Clinical Trials
9. Cost-Effectiveness of Brivaracetam Versus Other Antiepileptic Drugs Used as Adjunctive Treatment for Focal Seizures in the Uk: A Discrete Event Simulation Model
10. Applying The Accepted Techniques of Indirect Treatment Comparison to Meet Payer Needs For Brivaracetam Versus Adjunctive Antiepileptic Medications for The Treatment of Focal Seizures In Adult Patients. Do they reflect the need for individualised patient care in heterogeneous populations in epilepsy?
11. Do Accepted Techniques for Indirect Comparative Effectiveness Reflect the need for Individualized Patient Care in Heterogeneous Populations? The Case of Brivaracetam Versus Adjunctive Antiepileptic Medications for the Treatment of Adult Patients with Focal Seizures
12. Dapagliflozin Versus a Dipeptidyl Peptidase 4 Inhibitor (DPP4) Both Added to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM): Impact on Health, Quality of Life and Costs in the Turkish Clinical Setting
13. A Systematic Literature Review And Network Meta-Analysis of Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for The Treatment of Painful Diabetic Peripheral Neuropathy
14. Cost-Effectiveness Analysis of Exenatide Once-Weekly Versus Dulaglutide, Liraglutide and Lixisenatide for the Treatment of Type 2 Diabetes Mellitus: An Analysis from the UK NHS Perspective
15. Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective
16. The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain
17. Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
18. The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective
19. Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
20. Determinants of Increasing the Likelihood for a Positive Drug Reimbursement Recommendation in Scotland
21. Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective
22. A Comparison of Factors Influencing Reimbursement and Coverage Decisions in Scotland (Smc), The Netherlands (Nzi) and Germany (G-Ba)
23. Cost-Effectiveness of Saxagliptin Compared To Glp-1 Analogues As An Add-On To Insulin in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
24. Factors Influencing Dutch Drug Reimbursement Recommendations; A Database Analysis
25. The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus a DPP-4 Inhibitor in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
26. The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus Insulin in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
27. The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus Glipizide in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
28. A Comparison of Coverage and Reimbursement Decisions in Germany (AMNOG) and Scotland (SMC)
29. Overview of Health Economic Models in Type 2 Diabetes Mellitus (T2DM); A Systematic Literature Review
30. PIN68 Cost-Minimization Analysis of Caspofungin Versus Liposomal Amphotericin B for the Treatment of Febrile, Neutropenic Patients With a Presumed Fungal Infection in the Netherlands
31. RE1 Factors Influencing Drug Reimbursement Decision in Scotland
32. PHP104 Identifying Factors Influencing Drug Reimbursement in Scotland
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.